#ESMO26 | TALENT
Neoadjuvant T-DXd showed very low pCR rates in HR+/HER2-low early breast cancer:
- T-DXd: 7%
- T-DXd + anastrozole: 3%
- T-DXd → chemotherapy: 9%
We should remember that pCR is a limited surrogate endpoint in HR+ disease. However, these results do not support T-DXd as an alternative to standard neoadjuvant chemotherapy.
Moreover, given the heterogeneity of HER2-low disease, I find it unsurprising that the success of T-DXd in the metastatic setting does not translate into similar outcomes in early-stage disease, despite the lower tumor burden.
4313 浏览 · 43 赞 · 19 转发 · 1 回复
Final results of TALENT: A neoadjuvant trial of T-DXd with or without anastrozole, or in sequence with chemotherapy for HER2-low, HR+ early-stage breast cancer
https://esmocongress.esmo.org- Vadim Lesan@vadim_lesan
@dr_yakupergun If you assume constant Hazard ratio ~effectiveness of T-DXd across different disease states - metastatic vs. localized than the metastatic benefits more in absolute terms. General principle of statistics
来源：Yakup Ergün · x.com